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Objectives: To estimate the direct total and component medical costs for inpatient 
and outpatient care for patients with schizophrenia in Tianjin, China. MethOds: 
Data were extracted from the Tianjin Urban Employee Basic Medical Insurance data-
base. Patients (N= 2125) who were aged ≥ 18 years, at least 1 diagnosis of schizophre-
nia and 12-month continuous enrollment after their first observed schizophrenia 
diagnosis between 2008 and 2010 were included. Psychiatric-related inpatient and 
outpatient direct medical costs were estimated. Results: During the study period, 
60.8% of patients had at least one inpatient admission and 39.2% used only outpa-
tient services. The mean (± SD) total annual cost for inpatients was $2771.9±2175.6, 
with 88.9% ($2465.4±2022.5) due to non-drug medical costs and 11.1% ($306.6±461.7) 
for medications. Total annual costs for the outpatient only group were $230.6±487.3 
with 4.4% ($10.1±40.8) for non-drug medical costs and 95.6% ($220.5±470.3) for medi-
cations. Antipsychotics accounted for 50.4% of the total annual medication costs 
in the inpatient group and 60.0% in outpatient only group. On average, inpatients 
had 2.2 psychiatric hospitalizations and 2.2 outpatient visits. Outpatient only group 
had 5.9 outpatient visits. The highest costs per psychiatric-related inpatient admis-
sion were general care and non-drug treatment (49.8%), followed by examinations 
(21.6%), bed fee (14.6%), and medications (7.8%). The majority of costs for outpatient 
visits were due to medications (96.2%). cOnclusiOns: Patients who were hospital-
ized for schizophrenia incurred considerably more costs than those who were only 
treated at outpatient setting in Tianjin China, primarily driven by non-drug medical 
care. This suggests that the use of more effective treatments to minimize the risk 
of hospitalization could lead to reduced total health care costs.
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Objectives: To estimate the health care resource utilization and direct medi-
cal costs of patients with schizophrenia in Tianjin, China. MethOds: Data were 
obtained from the Tianjin Urban Employee Basic Medical Insurance database. Adult 
patients with ≥ 1 diagnosis of schizophrenia and 12-month continuous enroll-
ment after the first observed schizophrenia diagnosis between 2008 and 2010 were 
included. Both all-cause and psychiatric-related resource utilization and direct 
medical costs were estimated. Two-sample t-test was used to assess cost differ-
ence. A multiple linear regression model was applied to identify factors associated 
with total cost. Results: A total of 2125 patients were included, with mean age 
of 52.3 years, 49.3% male and 55.7% retired. 60.8% of the patients experienced ≥ 1 
psychiatric-related hospitalizations during the study period. Median (min-max) 
length of stay was 88 (1-365) days per admission and 91 (1-365) days per patient-
year. 58.9% of the patients experienced ≥ 1 psychiatric related outpatient visits. 
Median number of outpatient visits was 4 (1-82). Mean (±SD) total all-cause and 
psychiatric-related direct medical costs were $2863.5±2638.4 and $1774.5±2123.3 
per patient-year respectively, with significant difference between hospitalized and 
non-hospitalized patients ($3953.0 vs. $1176.9, p< 0.001; $2771.9 vs. $230.6, p< 0.001). 
The regression model revealed that patients with more hospitalizations/outpatient 
visits and non-retired patients were more likely to incur higher psychiatric-related 
annual costs. cOnclusiOns: Costs related to treatment with schizophrenia was 
considerable in Tianjin China, driven mainly by psychiatric hospitalizations. Patients 
with psychiatric-related hospitalizations used more medical resources and had 
higher direct medical cost than patients who were not hospitalized.
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Objectives: The economic burden of Alzheimer disease goes beyond the direct 
health cost as the disease has significant economic and social impact on both 
patients themselves and their families (carers). Despite the fact that Greece is 
plagued by the economic crisis, with major cuts in health expenditure, very little 
is known about the cost of chronic diseases and the most cost-effective ways to 
manage them. The study’s’ aim is to estimate, for the first time in Greece, the cost of 
Alzheimer’s disease, per each severity stage, evaluating apart from the direct costs 
of disease, the cost of carers. MethOds: The pilot sample was 46 patients from 
two Alzheimer centers. A cost analysis was conducted from the socio-economic 
perspective. Data regarding the carers’ time were collected via a questionnaire 
developed by the researchers of this study and was partly based on the research 
tool CATS (Caregiver Activities Time Survey) as it was adopted by Jacobsen et al. 
(2011). Results: The total annual cost of the disease was estimated at € 12,140 (SD: 
6,555.9) for the mild stage (MMSE* 30-21), at € 13,735 (SD: 7,858.7) for the moderate 
stage (MMSE 20-11), and € 22,666 (SD: 8,467.2) for the severe stage (MMSE 10-0) (for 
outpatient cases), 87% higher compared to the mild stage of disease. On average, 
from the total cost of disease, 77% was the cost of the primary and the second-
ary caregiver, 8.7% is the cost of medication and 5% is the hospitalization cost. 
Productivity loss of the primary caregiver exceeds 5% of the total cost per patient in 
mild stage. cOnclusiOns: As the patient gets worse and goes from mild to more 
severe stages, the total health care cost increase. It is important, when possible, to 
prolong the stay of patients in the early stages of the disease.
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minimize selection bias. Patients in both groups were required to be at least 18 years 
old, and have continuous medical and pharmacy benefits 1 year pre- and 1 year 
post-index date. One-to-one propensity score matching was applied to compare 
follow-up health care costs and utilizations between patients with and without 
PTSD. Results: A total of 938,138 patients were identified for the PTSD and com-
parison cohorts. After 1:1 matching, a total of 333,303 of patients were matched from 
each group, and baseline characteristics were balanced. Patients diagnosed with 
PTSD used more health care resources for inpatient (8.57% vs. 2.58%, p< 0.01), emer-
gency room (13.45% vs. 7.15%, p< 0.01), physician office (99.59% vs. 55.67%, p< 0.01), 
outpatient (99.64% vs. 56.46%, p< 0.01), and pharmacy visits (89.97% vs. 56.47%, 
p< 0.01) than patients in the comparator cohort. The PTSD cohort also incurred 
higher health care costs for inpatient ($2,587 vs. $719, p< 0.01), emergency room 
($133 vs. $66, p< 0.01), physician office ($3,404 vs. $1,254, p< 0.01), outpatient ($3,735 
vs. $1,430) and pharmacy visits ($629 vs. $362, p< 0.01). cOnclusiOns: Study results 
suggest that the economic burden and health care utilizations were significantly 
higher for patients with PTSD versus those without.
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Objectives: To compare health care costs and utilizations between patients with 
anxiety versus those without in the U.S. veteran population. MethOds: A retro-
spective database analysis was performed using the Veterans Health Administration 
(VHA) Medical SAS datasets (01OCT2008-30SEP2012). Patients diagnosed with anxi-
ety were identified (ICD-9-CM: 300.xx) from October 01, 2009 through September 30, 
2011. The first diagnosis date was designated as the index date for the anxiety group. 
A group of non-anxiety patients of the same age, region, gender and index year 
were identified and matched by baseline Charlson Comorbidity Index (CCI) as the 
comparison group. The index date for the comparator group was randomly chosen 
to reduce the selection bias. Patients in both groups were required to be at least 18 
years old, and have continuous medical and pharmacy benefits 1 year before and 
1 year after the index date. One-to-one propensity score matching was applied to 
compare the health care costs and utilizations during the follow-up period between 
the anxiety and comparison groups, adjusted for baseline demographic and clinical 
characteristics. Results: A total of 928,724 patients were identified for the anxiety 
and comparison cohorts. After 1:1 matching, 338,373 of patients were matched from 
each group and the baseline characteristics were well-balanced. Patients with anxi-
ety had higher percentages of inpatient (11.03% vs. 2.74%, p< 0.01), emergency room 
(18.64% vs. 7.50%, p< 0.01), physician office (99.53% vs. 59.16%, p< 0.01), outpatient 
(99.68% vs. 59.91, p< 0.01) and pharmacy visits (91.42% vs. 59.13%, p< 0.01). The anxi-
ety group had higher expenditures in inpatient ($3,347 vs. $782, p< 0.01), emergency 
room ($204 vs. $68, p< 0.01), physician office ($3,527 vs. $1,435, p< 0.01), outpatient 
($3,948 vs. $1,621) and pharmacy visits ($745 vs. $429, p< 0.01) than the comparison 
group. cOnclusiOns: Results suggest that patients diagnosed with anxiety used 
significantly more health care resources and incurred significantly higher health 
care costs compared to patients without.
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Objectives: Increasing prevalence of dementia highlights the need for a better 
understanding of the cost burden for health policy makers. By descriptive analysis 
of specific cost impacts, cost-of-illness (COI) studies are an essential instrument 
for decision making and planning of health care services. Therefore the purpose of 
this study was to review COI studies of dementia in order to analyze cost compo-
nents and underlying methods in an international context. MethOds: A system-
atic review according to the PRISMA-guidelines was conducted from 2002-2012 in 
order to identify COI studies related to dementia, searching the PubMed, Cochrane, 
EMBASE and NHS Economics Evaluations databases. Annual outcomes per patients 
were analyzed for total, direct, indirect and informal costs. Results: In total 25 
studies were evaluated. Total costs showed an annual range from USD 3.512 to USD 
59.526 in 14 health care systems. This is due to the fact, that the composition of cost 
components and corresponding methods indicated a large heterogeneity in terms 
of both – study characteristics (e.g. diagnosis, care setting, disease stratification) 
and composition of cost components. The majority of studies (92%, n= 23) included 
direct costs, however different cost components and underlying measurements 
were applied. Almost two thirds (60%, n= 15) of the studies included informal costs, 
whereas 9 used the replacement cost approach and 6 studies the opportunity cost 
approach. cOnclusiOns: Outcomes of COI studies in dementia indicate a large 
range, due to differences in health care systems, but also because of methodo-
logical approaches and cost components included. Dementia as a long-lasting and 
progressive disease affects multiple cost dimensions and thereby poses a complex 
challenge for policy makers. In addition, international guidelines on cost analysis 
of dementia are lacking. Standards regarding the methodology of COI studies in 
dementia by the scientific community would be useful. Funded by the European 
Commission, ICT-FP7, project-ID-287509.
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